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Abstract
Most interventions in critically unwell patients with septic shock are poorly supported by evidence, in
part reflecting the difficulty of conducting trials in this heterogeneous group. Four important clinical
trials in 2001-2 appeared to demonstrate mortality benefits associated with early goal-directed
resuscitation, intensive glycaemic control, physiological-dose steroid replacement and activated
protein C. However, recent evidence has not confirmed the beneficial effect of these interventions.
Introduction and context
Early in 2008, the Surviving Sepsis Campaign updated
guidelines for the management of septic shock [1].
Although endorsed by a large number of international
organizations (but notably not the Australian and New
Zealand Intensive Care Society [2]), previous guidelines
had been controversial for their support by the pharma-
ceutical industry, and for some of the previous recom-
mendations advocating interventions that were not well
supported by the evidence [3]. Whatever the criticisms of
the specific recommendations, evidence does suggest
that educational programs based on implementing the
guidelines are associated with improved outcomes in
observational studies [4,5].
Four landmark studies published in 2001 and 2002
appeared to show improvements in mortality associated
with certain therapeutic strategies: the use of physiolo-
gical-dose steroid replacement [6]; the strict maintenance
of blood sugar by insulin infusions [7]; the use of early
goal-directed fluid resuscitation [8]; and the use of
activated protein C (drotrecogin alfa) [9]. The updated
guidelines take a more balanced approach to recom-
mendations, particularly in the light of recent published
trials (Table 1). Unfortunately, these studies appear to
have joined the shortlist of promising strategies that have
been tempered by practical considerations and later
studies [10].
Recent advances
Steroid replacement revisited
In 2002, a multicentre trial of physiological-dose steroid
replacement against placebo in patients with septic shock
was published which suggested that the use of hydro-
cortisone and fludrocortisone at 'stress replacement' doses
was associated with a reduction in mortality in the
subgroup of patients that had 'relative adrenal insuffi-
ciency' [6]. The effect on surrogate endpoints, such as the
durationofshock anddurationofsurvival,appearedtobe
consistent with the effect of steroid replacement.
However, several concerns were raised, resulting in
doubts regarding the generalizability of this study.
First, the primary endpoint in all patients was not
statistically different at 28 days, with the benefit seen
primarily in the subgroup defined by a poor response to
stimulation with adrenocorticotropic hormone (ACTH).
The overall mortality and the proportion of patients with
relative adrenal insufficiency seemed high; the use of
etomidate, a known inhibitor of adrenal function, may
have contributed to the latter [11,12]. In this study [6],
all assays were performed at a central laboratory, and
studies have demonstrated significant heterogeneity
between different cortisol assays [13].
The CORTICUS study has recently been published,
examining the effect on mortality of hydrocortisone on
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patients received etomidate (19%), a high proportion
had relative adrenal insufficiency (51%) and overall
mortality was lower than in the previous study [6]. The
use of physiological-dose hydrocortisone was not
associated with a reduction in mortality (mortality
benefit). Although the duration of shock was shorter in
patients receiving hydrocortisone, the incidence of
recurrent septic shock was also higher. The Surviving
Sepsis Guidelines have been updated to reflect this, with
hydrocortisone now only recommended for patients not
responding to fluids and vasopressors, and the ACTH
stimulation test no longer routinely recommended [1].
Insulin infusions revisited
In 2001, Van den Berghe and colleagues [7] published a
clinical trial in which surgical patients in intensive care
were randomized to receive either intensive glycaemic
control using an insulin infusion, or standard treatment.
The target blood sugar in the intervention group was 4.4
to 6.1 mmol/l and was achieved by use of an insulin
infusion. Intensive glycaemic control was associated with
a 3.4% reduction in mortality, with benefits confined to
the subgroup of patients that had a length of stay
exceeding five days.
However, concerns focused on the poor glycaemic
control in the comparator arm, in which blood glucose
was maintained between 10 and 11.1 mmol/l; in
addition, patients were given an unusual feeding
protocol. Other investigators also had difficulties in
implementing the protocol without a significant rate of
hypoglycaemia. Furthermore, the group studied
included only post-surgical patients with a low level of
mortality, and uncertainty remained over the benefit of
glycaemic control in medical patients.
Table 1. Selected randomized controlled trials in severe sepsis and septic shock
Study Patient group Intervention/comparator Outcomes Comments
Physiological-dose steroids
Annane, 2001 [5] Septic shock (n = 300) Hydrocortisone (50 mg iv
q 6 h) and fludrocortisone
(0.1 mg po daily) for 7 days
vs placebo
28-day mortality:
5 vs 61%
(P = 0.09)
Benefit seen in ACTH non-responders
(63 vs 53%, P = 0.04). Included patients on
etomidate (n = 77) prior to change in
protocol
CORTICUS, 2008 [14] Septic shock (n = 499) Hydrocortisone (50 mg
iv q 6 h) for 5 days vs
placebo
28-day mortality:
3 vs 32%
(P = 0.51)
Patients on etomidate (n = 96) not excluded.
No benefit in ACTH non-responders (39 vs
36%). Increased incidence of superinfection in
steroid group (33 vs 26%)
Intensive glycaemic control
Van den Berghe, 2001
[7]
Surgical ICU patients
requiring mechanical
ventilation (n = 1548)
Insulin infusion to achieve
target glucose 4.4-6.1
mmol/l vs target glucose
10.0-11.1 mmol/l
In-hospital mortality:
7.2 vs 10.9%
(P = 0.01)
Benefit seen in patients requiring >5 days
intensive care (26 vs 17%). Difference in death
due to incident severe sepsis. Increased
proportion with hypoglycaemia (5.1 vs 0.8%)
Van Den Berghe, 2006
[15]
Medical ICU patients
(n = 1200)
Insulin infusion to achieve
target glucose 4.4-6.1
mmol/l vs target glucose
10.0-11.1 mmol/l
In-hospital mortality:
37.3 vs 40.0%
(P = 0.33)
Higher rates of hypoglycaemia (18.7 vs 3.1%,
P < 0.001)
VISEP, 2008 [16] Severe sepsis or septic
shock (n = 537)
Insulin infusion to achieve
target glucose 4.4-6.1
mmol/l vs target glucose
10.0-11.1 mmol/l
28-day mortality:
24.7 vs 26.0%
(P = 0.74)
Factorial trial with pentastarch. Higher pro-
portion of patients with hypoglycaemia
(17 vs 4.1%, P < 0.001)
Early goal-directed resuscitation
Rivers, 2001 [8] Patients presenting to
ED with severe sepsis
or septic shock
(n = 263)
Therapy guided by SvO2
monitoring vs standard
resuscitation
(see text)
In-hospital mortality:
30.5 vs 46.5%
(P = 0.009)
Single-centre study, patient management in
emergency department
Drotrecogin alfa
PROWESS, 2001 [9] Severe sepsis
(n = 1690)
Drotrecoginalfa(24μg/kg/h)
for 96 h vs placebo
28-day mortality
24.7 vs 30.8%
(P = 0.005)
Mortality benefit seen in high-risk patients
only (in subgroup analysis). Increase in serious
bleeding (3.5 vs 2%)
ADDRESS, 2005 [20] Severe sepsis but low
risk of death (either
APACHE II score < 25
or single organ failure)
(n = 2640)
Drotrecoginalfa(24μg/kg/h)
for 96 h vs placebo
28-day mortality:
18.5 vs 17%,
(P = 0.34)
Increase in serious bleeding (2.4 vs 1.2%,
P = 0.02)
RESOLVE, 2007 [21] Children < 18 years
with septic shock
(n = 477)
Drotrecoginalfa(24μg/kg/h)
for 96 h vs placebo
28-day mortality
17.2 vs 17.5%,
(P = 0.93)
No difference in time to resolution of organ
dysfunction
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glycaemic control in medical patients. In a follow-up
study, intensive glycaemic control was not associated
with a mortality benefit in a medical intensive care unit,
and although a benefit was seen in a subgroup of
patients with a length of stay exceeding three days, this
group could not be identified prospectively [15].
Intensive glycaemic control was not associated with a
mortality benefit in another clinical trial in interdisci-
plinary intensive care units that was stopped early
because of the high incidence of hypoglycaemia [16].
Faced with the uncertainty regarding the risks and
benefits of intensive glycaemic control, the Surviving
Sepsis Guidelines now recommend a more modest
blood glucose target of less than 8.3 mmol/l, despite
the lack of supporting evidence for this target [1]. A large
clinical trial, NICE-SUGAR, has been initiated in
Australia and Canada and will hopefully define the
appropriate glucose targets and patient group [2].
Early goal-directed resuscitation revisited
Aggressive early resuscitation is supported by the early
goal-directed therapy (EGDT) protocol, which attempts
to optimize several haemodynamic parameters within
the first 6 hours in the emergency department. Resuscita-
tion measures include the administration of fluids,
pressor and inotropic agents and red cell transfusion.
The intervention goals included central mixed venous
oxygen saturation (SvO2) that was measured with a
specialized central venous catheter. Use of a protocol
targeted at achieving an SvO2 of greater than 70%, in
addition to the goals set in the control group, was
associated with a mortality benefit when compared with
a single-centre study of a protocol guided by central
venous pressure and routine haemodynamic markers
only [8].
Some have argued that it is the timing of the intervention
that is associated with benefit rather than the use of
specific outcome measures. This is supported by a meta-
analysis of studies that showed that early intervention
was associated with a mortality benefit, but later
intervention was not [17]. Analogously, the administra-
tion of antibiotics early was also associated with reduced
mortality in an observational study [18].
Several clinical trials have been initiated to try to confirm
the observed benefit of the EGDT protocol, which has
not been widely adopted in its original form. As an
indicator of the uncertainty associated with this inter-
vention, clinicians are readily participating in two large
clinical trials that have recently been initiated to resolve
the question.
Activated protein C revisited
Many unsuccessful attempts have been made in the past
to modulate the immune response in severe sepsis. In
2001, the PROWESS study suggested that a significant
benefit was seen in a placebo-controlled trial of
drotrecogin alfa [9]. In this study, there was a 6.1%
reduction in 28-day mortality. However, the very high
cost of the drug, the question of whether the benefit was
restricted to a particular patient group, and controversies
around the approval process and marketing of the drug
led to poor uptake of this therapy [3,19]. A subsequent
subgroup analysis appeared to demonstrate benefit only
in patients at high risk of death, and later trials in less
severely unwell adult patients [20], and in children [21]
have been negative. The clinical uncertainty surrounding
the efficacy of drotrecogin alfa has led to calls for a repeat
trial to confirm the findings of the PROWESS trial [22],
and a clinical trial was initiated in late 2006.
Implications for clinical practice
Sepsis bundles
Although not explicitly spelled out in the guidelines, the
general message from recent studies is that protocol-
driven management that addresses the organ dysfunc-
tion associated with severe sepsis early on appears to be
associated with improved outcomes. Such protocols
have been termed 'sepsis bundles'. It is unclear which
component of the EGDT is associated with improve-
ments in mortality; for example, in a large Spanish study,
mortality fell after implementation of an educational
campaign based on the 'sepsis bundles', despite the post-
intervention cohort patients achieving benchmark goals
for central venous pressure and central venous oxygen
saturation in only 27% and 11% of cases, respectively,
with no significant difference in the time taken to achieve
them [5]. Similarly, the proportion of patients in which
drotrecogin alfa was considered for use rose from 44 to
52%, but it was only actually used in 56%: it is difficult
to see how merely considering to use a medication might
have an impact on mortality.
Mortality benefits in severe sepsis appear to be more
linked to the early and systematic measurement and
management of organ dysfunction, and are less depen-
dent on the choice of the precise measure and specific
intervention. The appropriate blood glucose target, the
use of cardiac output monitoring, central venous
oximetry and the choice of inotropes will continue to
be debated. Recent trials have failed to confirm the
promise of low-dose steroid replacement and intensive
glycaemic control, and considerable uncertainty remains
regarding the efficacy of drotrecogin alfa. Ongoing efforts
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continue to be the most effective management strategy.
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